Gastroparesis and severe gastrointestinal injuries Gastroparesis is the signature injury in GLP-1 litigation
The 2024 market share figures represent a significant shake-up, with Express Scripts leapfrogging the long-time leader, CVS Caremark
Case 2: Obfuscation of an Actionable BI-RADS Finding Following the Use of a GLP-1 Agonist A 44-year-old woman with recent history of 40 lb
There has been increased interest in time-restricted eating and intermittent fasting to improve metabolic variables, although with mixed, and modest, results
(For instance: Among cancer risks that the people faced were radiation and drinking water tainted with arsenic .) stigma: A disgrace, source of shame or a stain on ones reputation often not justifiably due to something that one did, experienced or represents to others
Plaintiffs in emerging Ozempic and Wegovy lawsuits claim that the manufacturer expanded use of these drugs aggressively while failing to fully disclose potential risks, including severe gastrointestinal complications and possible vision injuries
